hec88473
Recombinant proteinexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2021 (NCT04829123)
Timeline
Indications
Mechanism of action
FGFR1 agonist
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06148649 | Phase 2 | Dec 10, 2023 | TaiGen Biotechnology Co., Ltd. |
| NCT05943886 | Phase 1 | Aug 11, 2021 | Jinlin University, TaiGen Biotechnology Co., Ltd. |
| NCT04829123 | Phase 1 | May 29, 2021 | Scientia Clinical Research Limited Sydney, TaiGen Biotechnology Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TaiGen Biotechnology Co., Ltd. | For profit | 3 | 3 | 2 | 2021 |
| Jinlin University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1